Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

China flag China · Delayed Price · Currency is CNY
41.19
+1.14 (2.85%)
Apr 29, 2026, 3:00 PM CST
14.00%
Market Cap 12.91B
Revenue (ttm) 2.98B
Net Income (ttm) 937.93M
Shares Out 322.32M
EPS (ttm) 2.91
PE Ratio 13.76
Forward PE n/a
Dividend 1.76 (4.35%)
Ex-Dividend Date n/a
Volume 5,274,859
Average Volume 3,003,429
Open 40.60
Previous Close 40.05
Day's Range 40.55 - 41.60
52-Week Range 34.93 - 57.98
Beta 0.38
RSI 47.89
Earnings Date Apr 29, 2026

About SHA:600211

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-releas... [Read more]

Sector Healthcare
Founded 1999
Employees 671
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600211
Full Company Profile

Financial Performance

In 2025, SHA:600211's revenue was 2.98 billion, an increase of 6.23% compared to the previous year's 2.81 billion. Earnings were 937.93 million, a decrease of -10.78%.

Financial Statements

News

There is no news available yet.